BioHarvest Sciences launches buyback of up to 5% of shares
Published: 08:40 29 Sep 2026 EDT
BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) said Tuesday its board has authorized a share repurchase program covering up to 5% of its outstanding common shares.
The company, which develops and manufactures proprietary plant-based compositions for customers, partners and its own portfolio, will structure the program as a normal course issuer bid, in line with Canadian practice.
The bid allows for the purchase of a maximum of 1,133,392 shares, the most permitted in any 12-month period under a normal course issuer bid.
The board believes the market price of the common shares may not fully reflect the underlying value of the business and its future growth prospects, and sees the flexibility to repurchase shares as an effective allocation of capital that serves the company and its shareholders.
"We believe BioHarvest today is a substantially different company from the one reflected in our current market valuation," CEO Dr Zaki Rakib said.
"We have evolved from a company built primarily around VINIA into a technology-driven company with a proprietary Botanical Synthesis platform capable of developing and manufacturing multiple high-value plant-derived molecules across various industries."
Rakib said programs in natural sweeteners, rare fragrances and other high-value compounds are advancing toward commercialization, creating the potential for manufacturing revenues and royalties in addition to the existing VINIA business, which he described as a meaningful asset with significant operating leverage as it scales.
"In simple terms, we are investing in the asset we know best, BioHarvest," he said.